IL-13Rα2 chimeric antigen receptors and methods of use
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsRaj K. Puri, Bharatkumar H. Joshi
Life of this patent
Estimating the term…
Abstract
Immunotherapies, particularly chimeric antigen receptors targeting IL-13Rα2 and their use for treating cancer are provided. A single chain fragment variable (scFv) that specifically binds IL-13Rα2, chimeric antigen receptors (CARs) including the IL-13Rα2 scFv, nucleic acids encoding the CARs, vectors including the nucleic acids encoding the CARs, and immune cells expressing the CARs are provided. Also provided are methods of treating a subject with cancer, including administering to the subject an immune cell expressing an IL-13Rα2 scFv-CAR alone or in combination with other cancer therapies.
Claims20
A single-chain fragment variable (scFv) that specifically binds interleukin-13 receptor α2 (IL-13Rα2), wherein the scFv comprises an amino acid sequence comprising variable heavy chain (VH) domain complementarity determining region 1 (CDR1), CDR2, and CDR3 amino acid sequences of amino acid positions 31-35, 50-66, and 99-107 of SEQ ID NO:
- 1, respectively, and variable light chain (VL) domain complementarity determining region 1 (CDR1), CDR2, and CDR3 amino acid sequences of amino acid positions 157-167, 183-189, and 222-229 of SEQ ID NO:
- 1, respectively.
Dependencies are inferred from the claim text.